Applications for San Francisco (Batch 12) extended AGAIN through September 30th, 2021!

Learn more about investing in Helex Bio

Our team will get back to you soon to follow up on your inquiry.
Helex Bio
Accelerating Gene-Editing Based Next-Generation Therapies
Founded
2020
Employees*
1-10
Funding to Date*
$525K
Website
helex.bio/
Poulami Chuadhuri, Ph.D., CEO
The moment we have a database with a significant amount of data correlating guide RNA, its on-target efficiency and the off-target effects, we are definitely going to fast track the entire development process of CRISPR based therapies.
It costs $2 billion to develop a new gene-editing therapy, and $2 million to treat one patient.

Helex Bio enables gene therapy companies to design gRNAs & simulate outcomes of CRISPR edits to bring effective therapies to market faster with our Helex Platform™. The Helex Platform™ guides gene therapy companies in target identification, design and validation of efficient and safe gRNAs for creating functional impact with minimal significant off-targets. Additionally, the platform simulates edit outcomes to reliably develop therapy protocols.

The Helex Platform™ is powered by intelligent data driven deep-learning modeling using extensive high throughput next generation sequencing data derived from CRISPR edits on human cell lines. Helex not only gives reliable predictions through the Helex Platform™, but validate them in-house using cell-based assays and next generation sequencing to support with proven experimental data for high degree of reliability.